小剂量硝苯地平滴丸舌下含服治疗中重度高血压的随机双盲多中心研究
该研究为随机、双盲、阳性药物平行对照、多中心非劣效临床试验,纳入482例中重度高血压患者,比较舌下含服硝苯地平滴丸5 mg与10 mg的疗效与安全性。结果显示两组60分钟降压有效率及重复给药率无显著差异,但5 mg组不良事件发生率显著低于10 mg组。
要点
- 小剂量硝苯地平滴丸5 mg舌下含服降压疗效与10 mg常规剂量相当。
- 5 mg组不良事件/反应发生率为0,显著低于10 mg组的6.3%。
- 中重度高血压急性降压时可考虑小剂量舌下含服硝苯地平滴丸。
核心结论
- 小剂量硝苯地平滴丸5 mg舌下含服治疗中重度高血压的疗效与常规剂量10 mg相当,且安全性更好。
研究设计与样本
- 随机、双盲、阳性药物平行对照、多中心、非劣效临床研究,共纳入14家中心482例中重度高血压患者,试验组242例、对照组240例。
主要发现
- 给药后60分钟内试验组和对照组降压有效率分别为83.5%(202/242)和86.7%(208/240),组间差异无统计学意义(χ²=1.307,P=0.253)。
- 单次给药降压有效率试验组和对照组分别为85.6%(154/180)和87.2%(164/188),组间差异无统计学意义(χ²=0.221,P=0.639)。
- 重复给药率试验组和对照组分别为25.6%(62/242)和21.7%(52/240),组间差异无统计学意义(χ²=1.043,P=0.307)。
- 给药后120分钟内试验组不良事件/反应发生率为0,对照组为6.3%(15/240),组间差异有统计学意义(χ²=15.611,P<0.001)。
临床怎么用
- 中重度高血压急性降压时可选择小剂量硝苯地平滴丸5 mg舌下含服,疗效与10 mg相当且不良事件更少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the efficacy and safety of low dose sublingual nifedipine dripping pills (5 mg) in treating moderate and severe hypertension in comparison with normal dose (10 mg) of sublingual nifedipine dripping pills. Methods: This study was designed as a randomized, double-blind, positive drug parallel controlled, multi-center, non-inferiority clinical trial. Patients with moderate and severe hypertension were enrolled by 14 clinical trial centers, randomly divided into the trial group (sublingual 5 mg nifedipine dripping pills) and the control group (sublingual 10 mg nifedipine dripping pills). The changes in blood pressure were monitored continuously within 2 hours after the initial administration, repeated the dose in 20 minutes interval after the initial administration for up to additional 3 doses (maximum 4 doses) if the antihypertensive efficacy was not satisfactory. The efficacy of antihypertensive therapy between the two groups was evaluated by repeated administration rates and blood pressure changes at 60 minutes post the initial administration, and the safety of treatment was evaluated by recording adverse event rate of the two groups. Results: The anti-hypertensive effective rates at 60 minutes after sublingual administration were 83.5% (202/242) and 86.7% (208/240) respectively between the trial group and control group (χ(2)=1.307, P=0.253) . On the aspect of antihypertensive effectiveness at 60 minutes after single dose of sublingual administration, the anti-hypertension effective rates of the trial group and the control group were 85.6% (154/180) and 87.2% (164/188) respectively (χ(2)=0.221, P=0.639). Prevalence of the repeated administration was also similar between the two groups (25.6%(62/242) in the trial group and 21.7% (52/240) in the control group, χ(2)=1.043, P=0.307). On the safety aspect, there was no adverse events/reactions in the trial group, but there were 15 cases of adverse events/reactions occurred in control group (6.25%, χ(2)=15.611, P<0.001). Conclusions: In the treatment of moderate to severe hypertension, the antihypertensive efficacy of low dose nifedipine dripping pills is similar to that of conventional dosage, and the safety profile of low dose nifedipine dripping pills is better than that of the conventional dose. 目的: 评价小剂量硝苯地平滴丸舌下含服治疗中、重度高血压的有效性及安全性。 方法: 该研究为随机、双盲、阳性药物平行对照、多中心、非劣效临床研究。共纳入14家临床试验中心的中、重度高血压患者482例,其中试验组242例、对照组240例。试验组患者给予硝苯地平滴丸5 mg舌下含服,对照组患者给予硝苯地平滴丸10 mg舌下含服。初次给药后120 min内连续监测患者血压变化,如降压效果不满意则在初次给药后每间隔20 min重复给药1次,最多不超过3次(即用药总数不超过4次),以重复给药率和服药后60 min内血压变化来评价两组患者降压治疗的有效性,同时记录不良事件以评价治疗的安全性。 结果: 给药后60 min内,试验组和对照组患者降压有效率分别为83.5%(202/242)和86.7%(208/240),组间比较差异无统计学意义(χ(2)=1.307,P=0.253);试验组和对照组患者单次给药降压有效率分别为85.6%(154/180)和87.2%(164/188),组间差异无统计学意义(χ(2)=0.221,P=0.639);试验组和对照组患者重复给药率分别为25.6%(62/242)和21.7%(52/240),组间差异无统计学意义(χ(2)=1.043,P=0.307)。给药后120 min内,试验组患者不良事件/反应发生率为0,对照组不良事件/反应发生率为6.3%(15/240),组间差异有统计学意义(χ(2)=15.611,P<0.001)。 结论: 小剂量硝苯地平滴丸舌下含服治疗中、重度高血压患者疗效与常规剂量相当且安全性较好。.
引用
- Liu JH, Han YL, Zhang SY, et al. [Efficacy and safety of low dose sublingual nifedipine dripping pills (5 mg) in the acute treatment of moderate and severe hypertension: a randomized, double-blind, positive-drug parallel-controlled, multi-center clinical study]. Zhonghua Xin Xue Guan Bing Za Zhi. 2019. PMID: 31142081. doi:10.3760/cma.j.issn.0253-3758.2019.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。